GH/IGF1 axis disturbances in the fibromyalgia syndrome: Is there a rationale for GH treatment?

Pituitary

Volumn 17, Issue 3, 2014, Pages 277-283

  Cuatrecasas, G ^a   Alegre, C ^b   Casanueva, F F ^c  

^a CENTRO MÉDICO TEKNON   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adult growth hormone deficiency; Fibromyalgia; GH resistance; Growth hormone; IGF1; Quality of life

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARGININE; CLONIDINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA; PLACEBO; PYRIDOSTIGMINE; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C RECEPTOR; TRAMADOL; HUMAN GROWTH HORMONE; RECOMBINANT PROTEIN; SOMATOMEDIN C;

ADD ON THERAPY; ADRENERGIC ACTIVITY; ARTICLE; CARPAL TUNNEL SYNDROME; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; GROWTH HORMONE DEFICIENCY; HEADACHE; HEALTH CARE QUALITY; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN TOLERANCE TEST; LEG EDEMA; MULTICENTER STUDY (TOPIC); MUSCLE FUNCTION; NEUROPROTECTION; OLIGODENDROGLIA; PAIN ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; REM SLEEP; SLEEP DISORDER; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; DEFICIENCY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

FIBROMYALGIA; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

EID: 84905706199     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0486-0     Document Type: Article

References (57)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, Mccain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160-172 (Pubitemid 20098653)
2. Wolfe F (2010) New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 62(5):583-584
3. Martinez-Lavin M (2001) Overlap of fibromyalgia with other medical conditions. Curr Pain Headache Rep 5:347-350
4. de Alegre MC, Sellas FA (2008) Fibromyalgia: feeling and pain. Med Clin (Barc) 131(13):503-504
5. de Alegre MC, Alejandra-Pereda C, Betina-Nishishinya M, Rivera J (2005) Systematic review of pharmacologic treatment in fibromyalgia. Med Clin (Barc) 125(20):784-787
6. Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB (2010) Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 37(10):2156-2166
7. Owen RT (2008) Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 44(9):653-660
8. Carmona L, Ballina J, Gabriel R, Laffon A (2001) The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60:1040-1045 (Pubitemid 32989176)
9. Mäkelä M, Heliövaara M (1991) Prevalence of primary fibromyalgia in the Finnish population. BMJ 303(6796):216-219
10. Mease P (2005) Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 75:6-21
11. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ (2003) Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 30:1318-1325 (Pubitemid 36666360)
12. Lamotte M, Maugars Y, Le Lay K, Taïeb C (2010) Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. Clin Exp Rheumatol 28(6 Suppl 63):S64-S70
13. Thomas E, Ginies P, Blotman F (1999) Fibromyalgia as a national issue: the French example. Baillieres Best Pract Res Clin Rheumatol 13:525-529 (Pubitemid 30052727)
14. Department of Health (2006) The musculoskeletal services framework. Department of Health, London
15. Rivera J, Rejas J, Esteve-Vives J, Vallejo MA (2009) Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 27(5 Suppl 56):S39-S45
16. Staud R, Robinson ME, Price DD (2007) Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain 8:893-901 (Pubitemid 350008124)
17. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK (2007) Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 27:10000-10006 (Pubitemid 47404015)
18. Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ (2008) Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 35:1371-1377
19. Bennett RM (1989) Beyond fibromyalgia: ideas on etiology and treatment. J Rheumatol 19:185-191
20. Buskila D, Sarzi-Puttini P (2008) Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. Isr Med Assoc J 10:77-78 (Pubitemid 351649473)
21. Bazzichi L, Rossi A, Giuliano T, De Feo F, Giacomelli C, Consensi A, Ciapparelli A, Consoli G, Dell'osso L, Bombardieri S (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115-2120 (Pubitemid 350120351)
22. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F et al (2007) The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 10:13-25 (Pubitemid 46440564)
23. Izquierdo-Alvarez S, Bocos-Terraz JP, Bancalero-Flores JL (2008) Is there an association between fibromyalgia and below-normal levels of urinary cortisol? BMC Res Notes 1:134
24. Giesecke T, Williams DA, Harris R, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ (2003) Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 48(10):2916-2922 (Pubitemid 37280621)
25. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D (1998) The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 83(1):107-116 (Pubitemid 28498319)
26. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM (1997) Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24:1384-1389 (Pubitemid 27353385)
27. Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M (2010) High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 95(9):4331-4337
28. Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia- Pesquera F, Casanueva FF, Dieguez C (1999) The growth hormone (GH)- releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 84:3378-3381 (Pubitemid 30646970)
29. Denko CW, Malemud CJ (2005) Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int 25:146-151 (Pubitemid 40468939)
30. Yuen KC, Bennett RM, Hryciw CA, Cook MB, Rhoads SA, Cook DM (2007) Is further evaluation for growth hormone (GH) deficiency necessary in fibromyalgia patients with low serum insulin-like growth factor (IGF)-I levels? Growth Horm IGF Res 17:82-88
31. Griep EN, Boersma JW, de Kloet ER (1994) Pituitary release of growth hormone and prolactin in the primary fibromyalgia syndrome. J Rheumatol 21:2125-2130 (Pubitemid 24352364)
32. Dinser R, Halama T, Hoffmann A (2000) Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol 27:2482-2488
33. Paul-Savoie E, Marchand S, Morin M, Bourgault P, Brissette N, Rattanavong V, Cloutier C, Bissonnette A, Potvin S (2012) Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol J. 6:296-302
34. Paiva ES, Deodhar A, Jones KD, Bennett R (2002) Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 46:1344-1350 (Pubitemid 34525844)
35. Ferraccioli G, Guerra P, Rizzi V, Baraldo M, Salaffi F, Furlanut M, Bartoli E (1994) Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol 21:1332-1334
36. Gianotti L, Broglio F, Aimaretti G, Arvat E, Colombo S, Di Summa M, Gallioli G, Pittoni G, Sardo E, Stella M, Zanello M, Miola C, Ghigo E (1998) Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J Endocrinol Invest 21(2):115-121 (Pubitemid 28190607)
37. Bennett RM, Clark SC, Walczyk J (1998) A randomized, double-blind, placebo- controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104:227-231 (Pubitemid 28163166)
38. Cuatrecasas G, Riudavets C, Guell MA, Nadal A (2007) Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord 8:119
39. Cuatrecasas G, Alegre C, Fernandez-Solà J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, Lage M, Peinó R, Casanueva F, Liñan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M (2012) Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 153(7):1382-1389
40. Yanmaz MN, Mert M, Korkmaz M (2012) The prevalence of diabetes mellitus in a group of fibromyalgia patients. Rheumatol Int 32(4):871-874
41. Lathe R (2001) Hormones and the hippocampus. J Endocrinol 169:205-231
42. Sverrisdottir YB, Elam M, Caidahl K, Soderling AS, Herlitz H, Johannsson G (2003) The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 21:1905-1914 (Pubitemid 37290109)
43. Chrousos GP, Kino T (2007) Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10:213-219 (Pubitemid 46789478)
44. Przewlocki R, Przewlocka B (2005) Opioids in neuropathic pain. Curr Pharm Des 11:3013-3025 (Pubitemid 41158089)
45. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic- pituitary-adrenal axis function. Endocrinology 148:1574-1581 (Pubitemid 46457104)
46. Aberg ND, Johansson UE, Aberg MA, Hellstrom NA, Lind J, Bull C, Isgaard J, Anderson MF, Oscarsson J, Eriksson PS (2007) Peripheral infusion of insulin-like growth factor-I increases the number of newborn oligodendrocytes in the cerebral cortex of adult hypophysectomized rats. Endocrinology 148:3765-3772 (Pubitemid 47105860)
47. Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 35:81-90
48. Isgaard J, Aberg D, Nilsson M (2007) Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 32:103-113
49. Webb SM, de Andrés-Aguayo I, Rojas-García R, Ortega E, Gallardo E, Mestrón A, Serrano-Munuera C, Casamitjana R, Illa I (2003) Neuromuscular dysfunction in adult growth hormone deficiency. Clin Endocrinol (Oxf) 59:450-458 (Pubitemid 37188175)
50. Staud R (2006) Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des 12:23-27
51. McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G (1999) Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 516:583-592 (Pubitemid 29204460)
52. LeRoith D, Roberts CT Jr (1991) Insulin-like growth factor I (IGF-I): a molecular basis for endocrine versus local action? Mol Cell Endocrinol 77:C57-C61
53. Stewart CE, Rotwein P (1996) Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 271:11330-11338 (Pubitemid 26155970)
54. Guneli E, Kazikdas KC, Kolatan E (2007) Ghrelin may attenuate proinflammatory cytokine-mediated neuropathic pain. Med Hypotheses 69(2):356-360
55. Commentary: The basis for medical therapy of fibromialgia with growth hormone. Malemud C. Pain 2012; 1342-1343
56. McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK (2003) Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 30(4):809-814 (Pubitemid 36402777)
57. Jones KD, Deodhar AA, Burckhardt CS, Perrin NA, Hanson GC, Bennett RM (2007) A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulinlike growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exercise. J Rheumatol 34(5):1103-1111 (Pubitemid 46774857)